BiotechTube

Intravenous Paricalcitol

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Endstage Renal Disease

Conditions

Endstage Renal Disease, Secondary Hyperparathyroidism

Trial Timeline

Sep 1, 2011 → Jan 1, 2018

NCT ID
NCT03023748

About Intravenous Paricalcitol

Intravenous Paricalcitol is a approved stage product being developed by AbbVie for Endstage Renal Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT03023748. Target conditions include Endstage Renal Disease, Secondary Hyperparathyroidism.

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03023748ApprovedUNKNOWN